<DOC>
	<DOCNO>NCT00004446</DOCNO>
	<brief_summary>The purpose study : 1 ) Determine effect fluoxetine treatment depersonalization disorder , 2 ) Assess durability treatment response patient , 3 ) Assess improvement psychiatric disability patient , 4 ) Assess effect comorbid Axis I disorder ( depression , social phobia , panic/anxiety , obsessive-compulsive disorder ) Axis II personality disorder treatment outcome patient .</brief_summary>
	<brief_title>Study Fluoxetine Patients With Depersonalization Disorder</brief_title>
	<detailed_description>In trial , participant randomly assign receive either fluoxetine placebo . Treatment consist two phase ( acute treatment maintenance ) . In acute treatment phase , participant receive fluoxetine placebo daily 12 week . Participants follow every 2 week . In Maintenance phase , participant show significant improvement 12 week may continue treatment additional 6 month . In phase , participant follow every 4 week . Participants improve acute treatment phase may receive open fluoxetine , another appropriate medication , 3 month .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depersonalization</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>Inclusioin Criteria : Meets DSMIV criterion depersonalization disorder last month Prior concurrent bio chemotherapy Use follow within 2 week prior study entry : antipsychotic , anticonvulsant , stimulant , barbiturate , lithium , benzodiazepine , antidepressant Use MAO inhibitor investigational drug within 4 week prior study entry History fluoxetine use dose 10 mg least 6 week duration Hematologic , hepatic , renal , cardiovascular , pulmonary , metabolic , endocrine , systemic , gastrointestinal disease History mental disorder Current substance abuse Current eat disorder Current clinically unstable suicidal ideation Unstable medical illness Clinically unstable Clinically important abnormality lab test physical exam History seizure disorder abnormal electroencephalogram Hypersensitivity severe side effect fluoxetine Pregnancy breastfeeding . Women childbearing potential must use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>depersonalization disorder</keyword>
	<keyword>neurologic psychiatric disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>